Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This study will enroll participants with previously-treated advanced or inoperable gastric
cancer who have responded to first line platinum therapy into two treatment arms. In Arm A
participants will receive BGB-290; in Arm B participants will receive placebo. The purpose of
this study is to show that BGB-290 (versus placebo) will improve progression-free survival
(PFS) in participants with advanced or inoperable gastric cancer.